Avid Bioservices Inc (CDMO)

[entdoc]

r622, interesting stuff about Alzheimer's and inflammation, and a possible Bavi role in that disease. The "TREM2" gene mutation appears to be a player in only 1-2% of sufferers, but as Dr. Stefansson said in the article, "Although researchers have long noticed that the brain is inflamed in Alzheimer’s patients, he had dismissed inflammation as a major factor in the disease [until this study]." You probably remember SK specifying Alzheimer's disease when answering my question about BAVI's possible role in diseases other than cancer. Let's hope he has some specific insight in that regard. For instance, the article you cited is an overview and does not specify the types of inflammatory cells inhibited with the TREM2 genetic mutation. The assumption, of course, is that they are monocytes/macrophages if they are cells capable of gobbling amyloid frags. I've mentioned before here that one of the most intruguing and gratifying aspects of primary research on a therapeutic agent that has been established to be satisfactorily safe in humans is the many spin offs that occur along the way. Our knowledge in this field of antiphospholipid therapeutic possibilities is expanding rapidly, and we [here] have front row seats. Never mind the cost of admission!